Client News
Rentschler Biopharma Expands Leadership Team with Senior-Level Hires
10th August 2022
nova funds: Gesundheitsaktienfonds nova Steady HealthCare offiziell als nachhaltiges Investment klassifiziert
9th August 2022
ABIVAX PHASE 3 PROGRAM WITH OBEFAZIMOD IN ULCERATIVE COLITIS PROGRESSES WITH US IRB APPROVAL
4th August 2022
QUANTRO Therapeutics collaborates with Boehringer Ingelheim to develop drug candidates interfering with transcriptional regulators
3rd August 2022
Destiny Pharma: Publication of new data on NTCD-M3 confirms potential as an effective treatment for prevention of C. difficile infections
26th July 2022
There is no more content to load